XTL BIOPHARMACEUTICALS LTD - SPONSORED ADR NE (XTLB)

Historical Holders from Q1 2017 to Q4 2025

Type / Class
Equity / SPONSORED ADR NE
Symbol
XTLB on Nasdaq
Price per share
$0.5800
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
226,923
Total reported value
$265,800
% of total 13F portfolios
0%
Share change
-1,573
Value change
-$1,841
Avg sell value change
0%
Number of holders
4
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
As of 30 Sep 2025, XTL BIOPHARMACEUTICALS LTD - SPONSORED ADR NE (XTLB) has 4 institutional shareholders filing 13F forms. They hold 226,923 shares. .

Institutional Holders of XTL BIOPHARMACEUTICALS LTD - SPONSORED ADR NE (XTLB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 12,887 $7,474 +$7,474 58% 1
2025 Q3 226,923 $265,800 -$1,841 117.02% 4
2025 Q2 228,496 $261,097 -$24,978 114.07% 4
2025 Q1 248,304 $298,679 +$25,167 121.83% 4
2024 Q4 228,193 $462,739 -$7,273 202.63% 3
2024 Q3 231,858 $556,386 -$50,432 240.49% 3
2024 Q2 253,058 $613,370 -$16,662 239.93% 4
2024 Q1 258,944 $727,758 +$57,489 281% 5
2023 Q4 239,213 $241,734 +$136 101.06% 5
2023 Q3 239,879 $215,794 -$431 89.88% 4
2023 Q2 240,259 $240,367 -$600 100% 3
2023 Q1 240,659 $315,720 -$1,935 131.12% 2
2022 Q4 242,159 $293,358 -$2,420 121% 3
2022 Q3 443,047 $492,000 -$3,866 111.12% 3
2022 Q2 446,547 $678,000 -$2,759 151.84% 3
2022 Q1 447,859 $1,046,000 -$65,725 236.82% 4
2021 Q4 472,127 $1,307,000 -$67,908 276.57% 4
2021 Q3 487,426 $2,135,000 -$54,036 437.93% 6
2021 Q2 500,698 $1,999,000 -$29,157 399.22% 5
2021 Q1 508,501 $1,693,000 +$114,744 333.01% 6
2020 Q4 474,130 $1,437,000 +$85,428 302.94% 4
2020 Q3 446,243 $848,000 +$12,626 190.06% 4
2020 Q2 439,607 $699,000 +$3,043 158.88% 3
2020 Q1 437,707 $515,000 +$3,649 117.65% 3
2019 Q4 434,607 $594,000 -$60,051 136.76% 3
2019 Q3 481,451 $687,000 +$25,831 143.12% 6
2019 Q2 463,299 $927,000 -$2,958 200.11% 5
2019 Q1 464,799 $1,096,000 +$964 235.81% 5
2018 Q4 464,842 $804,000 -$65,735 172.96% 6
2018 Q3 97,539 $208,000 -$10,838 220.27% 4
2018 Q2 104,113 $193,000 +$113,891 184.63% 4
2018 Q1 43,951 $76,000 +$11,436 175.25% 4
2017 Q4 36,722 $84,000 -$23,281 229.79% 2
2017 Q3 49,712 $118,000 +$2,452 236.29% 4
2017 Q2 48,930 $155,000 +$38,506 315.86% 3
2017 Q1 36,841 $97,000 +$97,000 263.16% 3